00867 China Medical System Holdings Ltd.

NOTICE TO DISREGARD -- China Medical System Holdings Ltd.

NOTICE TO DISREGARD -- China Medical System Holdings Ltd.

SHENZHEN, CHINA, Dec. 21, 2022 (GLOBE NEWSWIRE) -- We are advised by China Medical System Holdings Ltd. that journalists and other readers should disregard the news release, "CMS (867.HK) Joins Hand with Incyte on Ruxolitinib Cream, Brings 1st Repigmentation Drug for Vitiligo Patient" issued December 6, 2022, over GlobeNewswire.



EN
21/12/2022

Underlying

00867China Medical System Holdings Ltd.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on China Medical System Holdings Ltd.

 PRESS RELEASE
Free
00867 China Medical S...

CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Ap...

CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China SHENZHEN, CHINA, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) recei...

January 30, 2026 1 EN
 PRESS RELEASE
Free
00867 China Medical S...

CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib ...

CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China SHENZHEN, CHINA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has...

December 15, 2025 1 EN
 PRESS RELEASE
Free
00867 China Medical S...

CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Isch...

CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China SHENZHEN, CHINA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the ...

December 11, 2025 1 EN
 PRESS RELEASE
Free
00867 China Medical S...

CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Rα ...

CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection MG-K10 Accepted in China SHENZHEN, CHINA, Oct. 30, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-de...

October 30, 2025 1 EN
 PRESS RELEASE
Free
00867 China Medical S...

CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Dr...

CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu® SHENZHEN, CHINA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on  27 October 2025, the Group through its subsidiary CMS VISION INTERNATIONAL MANAGEMENT LIMITED entered into a Distribution Agreement (the “Agreement”) with Novartis Pharma Services AG (“Novartis”) for Ranibizumab Injection (“Lucentis®”) and Brolucizumab Injection (“Beovu®”). In accordance with the Agreement, the Group has obtained the exclusive right to i...

October 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch